BioVie's Novel Therapeutic Shows Promise for Alzheimer's, Parkinson's, and Long COVID

BioVie's Approach to Neurodegenerative Diseases

• 💡 BioVie is developing a novel anti-inflammatory agent with broad applications in neurology, targeting diseases like Alzheimer's and Parkinson's.
• 🤝 The company is also involved in a nonprofit, Social Impact Partners, to foster collaboration between private, public, and government sectors for Alzheimer's patient support.

Alzheimer's Trial Results and Biological Aging

• 🎯 In Alzheimer's patients who complied with the protocol, BioVie's treatment slowed symptom progression by 68% in about six months, significantly outperforming current approved treatments.
• 🧬 The company's research also explored the impact of their therapeutic on biological aging, observing a deceleration of approximately five years in treated patients.
• 🔬 This effect is linked to reducing DNA methylation, a process associated with aging and diseases like Alzheimer's and Parkinson's.

Parkinson's Disease Treatment Progress

• ⚡ BioVie completed its first Parkinson's trial, focusing on patients with breakthrough 'off' symptoms where they could not move.
• ✅ Approximately one-third of patients on the drug entered the 'on' state, regaining motor control, compared to none on placebo.
• 💤 Improvements in sleep were also observed, suggesting potential for a broad-spectrum treatment for both motor and other Parkinson's symptoms.

Long COVID Therapeutic Development

• ⚠️ BioVie is addressing the 20 million Americans suffering from debilitating Long COVID symptoms like brain fog and fatigue.
• 🔬 The company is the only one to receive an NIH grant to test its therapeutic for Long COVID, as symptoms are tied to inflammation similar to their drug's mechanism.
• 📈 A trial enrolling 200 patients is underway at prestigious academic medical centers, with data expected later this year or early next.

Future Outlook and Clinical Trials

• 🗓️ BioVie anticipates significant data releases over the next six to nine months from ongoing Parkinson's and Long COVID trials.
• 🚀 The company is optimistic about the potential of its therapeutic to improve health outcomes for patients with neurodegenerative and post-viral conditions.